1-7 of 7
Cong Chen
Close
Sort by
Journal Articles

Pre-Existing Chromatin States Regulate KLF4 Binding to Eliminate Leukemia Stem Cells

Ting Lu, Shangda Yang, Cong Chen, Shan Liu, Guohuan Sun, Hui Cheng, Tao Cheng, Kuangyu Yen
Journal: Blood
Blood (2023) 142 (Supplement 1): 2757.
https://doi.org/10.1182/blood-2023-179013
Published: 2023
Journal Articles

A Novel Lncrna, Lncery, Interacts with Wdr82 to Regulate Erythroid Differentiation By Promoting Globin Gene Transcription

Shangda Yang, MD, Guohuan Sun, Peng Wu, MD PhD, Yijin Kuang, Cong Chen, Zhaofeng Zheng, Quan Gu, PhD, Caiying Zhu, Fanglin Gou, Zining Yang, Xiangnan Zhao, Liu Yang, Shihong Lu, Shi Lihong, Xue Lv, Fang Dong, PhD, Lihong Shi, Lai Guang Ng, Jing Liu, PhD, Hui Cheng, Tao Cheng
Journal: Blood
Blood (2020) 136 (Supplement 1): 2.
https://doi.org/10.1182/blood-2020-139258
Published: 2020
Journal Articles

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Madeleine Duvic, MD, Youn H Kim, MD, Timothy M Kuzel, MD, Theresa R Pacheco, MD, Francine M Foss, Sareeta Parker, Syed Rizvi, Cong Chen, Jean Marie Arduino, ScD, Elise A. Olsen, MD
Journal: Blood
Blood (2009) 114 (22): 1709.
https://doi.org/10.1182/blood.V114.22.1709.1709
Published: 2009
Journal Articles

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Clinical Trials & Observations
Guillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, Alessandra Ferrajoli, Jorge Cortes, William G. Wierda, Stefan Faderl, Charles Koller, Gail Morris, Gary Rosner, Andrey Loboda, Valeria R. Fantin, Sophia S. Randolph, James S. Hardwick, John F. Reilly, Cong Chen, Justin L. Ricker, J. Paul Secrist, Victoria M. Richon, Stanley R. Frankel, Hagop M. Kantarjian
Journal: Blood
Blood (2008) 111 (3): 1060–1066.
https://doi.org/10.1182/blood-2007-06-098061
Published: 2008
Includes: Supplemental data
Journal Articles

Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma.

Donna M. Weber, Sundar Jagannath, Amitabha Mazumder, Ronald Sobecks, Gary J. Schiller, Maria Gavino, Chantelle Sumbler, Carrie McFadden, Cong Chen, Justin L. Ricker, Syed Rizvi, Carol Oerth, Patricia Brownell, Mohamad A. Hussein
Journal: Blood
Blood (2007) 110 (11): 1172.
https://doi.org/10.1182/blood.V110.11.1172.1172
Published: 2007
Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Safety and Clinical Benefit to Patients with Advanced Cutaneous T-Cell Lymphoma (CTCL).

Madeleine Duvic, Elise A. Olsen, Debra Breneman, Theresa R. Pacheco, Sareeta Parker, Eric C. Vonderheid, Justin L. Ricker, Syed Rizvi, Cong Chen, Kathleen Boileau, Paulette Cooley, Larisa J. Geskin
Journal: Blood
Blood (2007) 110 (11): 2582.
https://doi.org/10.1182/blood.V110.11.2582.2582
Published: 2007
Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Madeleine Duvic, MD, Youn H. Kim, MD, Timothy M. Kuzel, MD, Theresa R. Pacheco, MD, Francine M. Foss, MD, Sareeta Parker, MD, Stanley R. Frankel, MD, Cong Chen, PhD, Justin L. Ricker, MD, PhD, Jean Marie Arduino, PhD, Sophia Randolph, MD, PhD, Victoria M. Richon, PhD, Elise A. Olsen, MD
Journal: Blood
Blood (2006) 108 (11): 399.
https://doi.org/10.1182/blood.V108.11.399.399
Published: 2006